Kristine Curtiss joined the iSTAR Medical team on 15 July 2024 with 24 years of clinical research experience in ophthalmology. Kristine is an accomplished and performance-driven leader, who has held senior positions in both biotech, medical device, and large pharma companies.
Her most recent experience was as Vice President, Clinical Operations at Iveric bio, Inc. where she oversaw the clinical study teams, North American regional monitoring team, data management, and clinical supply team that worked on the studies leading to FDA approval of Iverzay™ for Geographic Atrophy. She was instrumental in ensuring the smooth integration of her team following the 2023 acquisition by Astellas, where she has been Vice President Clinical Operations - Ophthalmology. Prior to Iveric/Astellas, Kristine held leadership positions at ophthalmic start-up companies such as PanOptica, Oraya Therapeutics, OPKO, and Eyetech Pharmaceuticals, which was acquired by OSI Pharmaceuticals. She spent the first 10 years of her career at Hoffmann La Roche where she started in the labs and eventually transitioned into Clinical Research.
Kristine has been a major contributor to 5 successful marketing applications: Iverzay™ for Geographic Atrophy, Macugen® for exudative Age-related Macular Degeneration, Xeloda® for breast and colorectal cancer, and Tasmar® for Parkinson's disease.
Kristine obtained a Bachelor of Science in Chemistry from the University of Delaware and a graduate certificate in Project Management from Rutgers University School of Business, both located in the US.
